• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

FibroGen Looks to Regroup After Rocky Q2 Results, Ongoing Challenges

cafead

Administrator
Staff member
  • cafead   Aug 08, 2023 at 10:32: AM
via FibroGen endured clinical setbacks and a leadership shake-up in recent months, but the California biotech remains optimistic about its path forward, the company said Monday during its second-quarter 2023 earnings report.

article source
 

<